The European Medicines Agency and the Heads of Medicines Agencies (HMA) have issued a joint statement confirming that biosimilars approved in the European Union are interchangeable with reference medicines or equivalent biosimilars.
The use of biosimilar medicines is already practiced in many Member States, incl. in Poland. The position thus unifies the approach of the European Union in this matter. As a result, more patients will be able to access biologica...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
